US Market News
3日前
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMPJune 3, 2026 3:02 AM
PR Newswire (US) LOS ANGELES, June 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: March 24, 2025 to March 12, 2026DEADLINE: July 6, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Immutep filed an SEC Form-K on January 30, 2026 that its TACTI-004 trial of eftilagimod alfa ("efti") was showing "strong operational progress." Despite this claim, the Company knew that the trial would fail to meet primary endpoints for efficacy. Based on these facts, Immutep's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com View original content:https://www.prnewswire.com/news-releases/immutep-limited-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--immp-302789500.htmlSOURCE DJS Law Group LLP Original: Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
makinezmoney
1月前
$IMMP: POster presentation on May 29th................
Better blow them away with it whatever they plan to discuss cuz this is in the doldrums here at $0.47.
No interest in it whatsoever.
Let it come down to $0.20s again and then maybe a nibble ahead of that
GO $IMMP
*************************************************************
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
By Immutep Limited | April 22, 2026, 8:00 AM
Share
IMMP
-1.89%
Immutep Limited ADR
SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States).
The accepted abstract, titled “Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients,” will be presented within the Developmental Therapeutics—Immunotherapy sessions by Professor Martin Forster from the UCL Cancer Institute, UK.
The poster will present cumulative clinical and translational data demonstrating that eftilagimod alfa (efti), an antigen-presenting cell (APC) activator targeting MHC Class II, induces rapid and sustained lymphocyte activation. Across multiple late-stage cancer studies1, immune activation markers were associated with improved overall survival outcomes in patients with metastatic disease, supporting the clinical relevance of eftilagimod alfa’s mechanism of action.
ASCO 2026 Poster Presentation Details
Title: Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients
Poster Session: Developmental Therapeutics—Immunotherapy
Date and Time: 30 May 2026, 1:30 PM-4:30 PM CDT
Poster Board: 359
Abstract #: 2569
About ASCO 2026
The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates and investment analysts to discuss cutting-edge clinical research and emerging therapeutics in oncology, and to gain insights to improve cancer care. More than 40,000 attendees from around the world are expected to participate in person and online to stay up to date on the latest advances across all areas of cancer research and to hear real-time insights from world-renowned experts. For additional information on the ASCO Annual Meeting, please visit www.asco.org.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com
This announcement was authorised for release by the CEO of Immutep Limited.
1 Please note that the abstract does not include data from the TACTI-004 study, as immune data collection for that trial has not yet been completed. All data presented were collected from earlier clinical trials, initiated prior to TACTI-004.
janetcanada
1月前
☯️***IMMP.....***Wondering About The Probability***.....& ***Out Of Curiosity???....
☯️***AI Overview
***Yes, a cancer-focused stock can reach or exceed $200, though this usually requires significant long-term growth, successful clinical trials, regulatory approvals, or acquisition, rather than rapid overnight success. While some established companies already trade above or near this level, smaller biotech firms often aim for this through "monster returns" over a decade-long horizon.
The Globe and Mail
The Globe and Mail
+2
☯️***Examples and Potential:
Targeted Growth: Some analysts projected that certain stocks, such as Exelixis (which was trading around $45-$50 in 2025), could potentially reach $200 over a 10 to 15-year period if they maintain strong compound annual growth rates (CAGR) through clinical success, such as with their candidate zanzalintinib.
High-Potential Biotech: Small-cap, specialized biotechs (e.g., CG Oncology) with best-in-class efficacy in specific areas like bladder cancer have seen sharp surges, with analysts highlighting potential for over 100% gains from their current prices.
Long-Term Horizon: The oncology drugs market is growing rapidly, with a projected
CAGR of 11.3%, increasing from roughly $220 billion in 2024 to over $500 billion by 2032. This sustained sector growth supports the potential for high-performing, specialized stocks to reach high price points over time.
The Globe and Mail
The Globe and Mail
+2
Key Drivers for High Stock Prices:
Breakthrough Technology: Companies focused on antibody-drug conjugates (ADCs) and next-generation immuno-oncology are highly sought after.
FDA Approvals: Successful Phase 3 trials and regulatory approval (e.g., of new treatments for non-muscle invasive bladder cancer) act as major catalysts.
Acquisitions: Smaller, successful biotech firms are frequently acquired by larger pharmaceutical companies, driving up their stock prices.
The Globe and Mail
The Globe and Mail
+3
Risks Involved:
High Volatility: Cancer stocks, especially small-cap biotechs, are highly volatile and carry significant risks of falling if drug trials fail or if they do not receive FDA approval.
Long Timeframes: Reaching a high dollar value like $200 often takes years, not weeks, and requires consistent, top-tier performance in a competitive landscape.
The Globe and Mail
The Globe and Mail
+2
Disclaimer: Stock investments, particularly in biotech, are highly speculative. It is important to do your own research or consult a financial advisor.
Here's Why This $50 Healthcare Stock Could Be the Next ...
Jul 20, 2025 — Can Exelixis get to $200? From its current stock price of approximately $45, Exelixis needs a compound annual growth rate (CAGR) o...
The Globe and Mail
3 Under-the-Radar Biotechs Under $5 That Could Soar 200%
Sep 9, 2025 — Chris Markoch - MarketBeat - Tue Sep 9, 2025. Investing in biotechnology stocks is typically reserved for speculative investors. F...
The Globe and Mail
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Dec 18, 2024 — Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent ...
The Globe and Mail
Show all
Dive deeper in AI Mode
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn moreLearn mo
janetcanada
1月前
☯️***IMMP ***Reading the Latest News.... Since IMMP is a Nasdaq Stock & Having Insiders & Institutions Holders....***IMO...The Potential Going Forward Looks Positive 🍀....
☯️***From Barchart.....
***https://www.barchart.com/stocks/quotes/IMMP/overview
☯️***.https://nz.finance.yahoo.com.....
👆️***Major Holders***.....
☯️***Insider Trading Screener- "Add symbol"......
***https://www.secform4.com › insider-trading-screener
☯️***Stock Titan
***https://www.stocktitan.net › news
☯️***.https://nz.finance.yahoo.com ›
☯️***OTC Markets- NEWS....
***https://www.otcmarkets.com
==========================================
☯️***.https://nz.finance.yahoo.com ›
***Major holders
***Insider roster
***Insider transactions
***Major holders
***Breakdown
0.01% % of shares held by all insiders
2.01% % of shares held by institutions
2.01% % of float held by institutions
29 Number of institutions holding shares
***Top institutional holders
Holder Shares Date reported % out Value
Blackrock Inc. 823.54k 31 Dec 2025 0.56% 507,795
Meridian Wealth Management, LLC 454.4k 31 Dec 2025 0.31% 280,183
Millennium Management Llc 106.75k 31 Dec 2025 0.07% 65,822
Two Sigma Investments, LP 94.59k 31 Dec 2025 0.06% 58,327
UBS Group AG 70.42k 31 Dec 2025 0.05% 43,419
Susquehanna International
and & more........
janetcanada
2月前
☯️***Very Interesting Post...."IMMP Target Price $8.64".....
☯️***AI Overview
☯️***Refinitiv is a major global provider of financial market data, infrastructure, and analytics, which was acquired by the London Stock Exchange Group (LSEG) in 2021 for $27 billion. Formerly the Financial & Risk business of Thomson Reuters, it rebranded to LSEG Data & Analytics, with its "Refinitiv Workspace" product now known as LSEG Workspace.
LSEG
LSEG
+4
***Key details about Refinitiv:
***What it does: Provides data, trading platforms, and insights to over 40,000 institutions in 190+ countries.
janetcanada
2月前
☯️*** IMMP ***......🤔
☯️***From Barchart.....
***https://www.barchart.com/stocks/quotes/IMMP/overview
☯️***.https://nz.finance.yahoo.com
☯️***Insider Trading Screener- "Add symbol"......
***https://www.secform4.com › insider-trading-screener
☯️***Stock Titan
***https://www.stocktitan.net › news
☯️***.https://nz.finance.yahoo.com ›
☯️***OTC Markets- NEWS....
***https://www.otcmarkets.com
🍀✔️***CEO of Immutep, Marc Voigt said: “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti. The FDA’s designation, based on very encouraging data from the EFTISARC-NEO trial, provides us with a potential direct step forward into a late-stage study in the neoadjuvant setting for STS.”
About Immutep
iHub News
2月前
Immutep Shares Surge After FDA Grants Orphan Drug Status to Cancer TherapyApril 15, 2026 10:53 AM
IH Market News
Immutep (NASDAQ:IMMP) shares jumped sharply on Wednesday after the company announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation (ODD) to eftilagimod alfa.Eftilagimod alfa is being developed as a treatment for soft tissue sarcoma (STS), a rare and complex group of cancers that arise in connective tissues such as muscle, fat, nerves and blood vessels.The FDA awarded the designation in recognition of the significant unmet medical need in STS. Immutep said the decision also highlights the therapeutic potential of eftilagimod alfa in this indication, supported by encouraging results from its Phase II EFTISARC-NEO study.The trial assessed the treatment in combination with radiotherapy and KEYTRUDA, providing positive clinical data in patients with soft tissue sarcoma.Marc Voigt, CEO of Immutep, said, “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti.”Immutep stock price
Original: Immutep Shares Surge After FDA Grants Orphan Drug Status to Cancer Therapy
INV4
2月前
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
April 15, 2026
SYDNEY, AUSTRALIA, April 15, 2026 — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need.
The FDA’s Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval.
This designation recognises the potential therapeutic relevance of efti in STS, supported by encouraging clinical data from the investigator-initiated Phase II EFTISARC-NEO trial which has been evaluating efti in combination with radiotherapy and KEYTRUDA® (pembrolizumab) in the neoadjuvant setting in patients with resectable soft tissue sarcoma. In 38 evaluable patients, the study met its primary endpoint, demonstrating a median tumour hyalinization/fibrosis of 51.5%, significantly exceeding the pre-specified target of 35% and historical benchmarks of ~15% with radiotherapy alone.1
These results were observed across multiple sarcoma subtypes and were supported by translational data showing immune activation consistent with efti’s mechanism of action, with a favourable safety profile and no delays to planned surgery.2
CEO of Immutep, Marc Voigt said: “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti. The FDA’s designation, based on very encouraging data from the EFTISARC-NEO trial, provides us with a potential direct step forward into a late-stage study in the neoadjuvant setting for STS.”
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
1. ESMO Congress 2025 Proffered Paper presentation, “EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma”.
2. CTOS 2025 Annual Meeting Oral Presentation, “Primary endpoint and translational correlates from EFTISARC-NEO: Phase II trial of neoadjuvant eftilagimod alfa (efti), pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma”.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Investors/Media:
Matthew Beck, astr partners
Ph: +1 (917) 415-1750; matthew.beck@astrpartners.com
This announcement was authorised for release by the CEO of Immutep Limited.
Link article
$IMMP 🗞️
iHub News
3月前
Immutep Shares Collapse After Lung Cancer Trial Halted for FutilityMarch 13, 2026 11:34 AM
IH Market News
Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would discontinue its Phase III TACTI-004 clinical trial following a futility review.The Independent Data Monitoring Committee (IDMC) recommended ending the study, which was evaluating eftilagimod alfa (“efti”) as a treatment for patients with first-line non-small cell lung cancer. After assessing the available safety and efficacy data, the committee concluded the trial was unlikely to achieve its intended objectives and advised stopping it for futility.Immutep said it will immediately cease patient enrollment and begin a structured wind-down of the trial. This process will include continued patient monitoring and the closure of clinical sites in accordance with regulatory and ethical requirements.Chief Executive Officer Marc Voigt said the company was both disappointed and surprised by the decision, particularly given the performance of efti in other clinical programs. Immutep is now conducting a full review of the available trial data to evaluate possible next steps for the therapy.Following the trial’s termination, the company indicated its existing cash resources are now expected to last well beyond the previously projected runway of the second quarter of 2027. An updated financial outlook will be provided once operational adjustments are completed and the trial data has been fully analyzed.Analysts quickly revised their views on the stock. Baird analyst Colleen Kusy downgraded Immutep from Outperform to Neutral, cutting the price target to $1.00 from $7.00. Citizens analyst Reni Benjamin also lowered the rating from Market Outperform to Market Perform, removing previously projected revenues tied to the non-small cell lung cancer indication.Although the company continues to run clinical studies in other disease areas, analysts believe the shares may trade largely in line with the broader market until new randomized trial results provide clearer signals on the pipeline’s prospects.Immutep stock price
Original: Immutep Shares Collapse After Lung Cancer Trial Halted for Futility
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Zardiw
2月前
glenn1919
2月前
Monksdream
1年前
Vector2112
2年前
DewDiligence
3年前
stocks2watch
4年前
sgunderbarth
5年前
ClayTrader
5年前
メールアドレスで登録
